Department of Radiation Oncology, Beaumont Health, Oakland University William Beaumont School of Medicine, Royal Oak, MI.
Department of Radiation Oncology, Beaumont Health, Oakland University William Beaumont School of Medicine, Royal Oak, MI.
Clin Lung Cancer. 2018 Mar;19(2):e185-e194. doi: 10.1016/j.cllc.2017.10.011. Epub 2017 Nov 20.
Currently, the ideal timing for postoperative radiotherapy (PORT) and chemotherapy is unknown. The present study evaluated their relative timing on overall survival (OS) using the National Cancer Database (NCDB).
The NCDB was queried for patients from 2004 to 2012 with resected non-small-cell lung cancer (NSCLC), pathologically involved N2 (pN2) nodes, and negative margins. All patients underwent adjuvant chemotherapy and external beam radiotherapy. The time to radiation (TTR) was determined from the date of surgery to the start of PORT, with the exclusion of those receiving PORT < 4 weeks or > 24 weeks postoperatively. Early and late TTR was dichotomized at 8 weeks after receiver operating characteristic analysis. Multivariate Cox regression analysis was conducted to predict the variables significantly associated with survival.
A total of 1629 patients were eligible for analysis. Of the 1629 patients, 703 had received PORT < 8 weeks and 926 had received PORT ≥ 8 weeks postoperatively. The receipt of PORT after 8 weeks was associated with better OS (P = .0044). No significant differences were found in survival in the concurrent group comparing early and later TTR (P = .9119). However, a significant OS benefit was found for sequential chemotherapy with an increased TTR (P = .0045). Older age, male sex, shorter distance traveled, increased nodal positivity, larger tumor size, higher Charlson/Deyo comorbidity score, and early TTR were associated with inferior survival on multivariate analysis.
A TTR of ≥ 8 weeks with sequential chemotherapy in the setting of PORT was associated with improved survival in patients with NSCLC with pN2 nodes.
目前,术后放疗(PORT)和化疗的理想时机尚不清楚。本研究使用国家癌症数据库(NCDB)评估了它们对总生存(OS)的相对时间。
从 2004 年至 2012 年,NCDB 对接受手术切除的非小细胞肺癌(NSCLC)、病理上有 N2(pN2)淋巴结受累且切缘阴性的患者进行了查询。所有患者均接受了辅助化疗和外照射放疗。从手术日期到 PORT 开始的时间确定为放疗时间(TTR),排除术后 4 周内或 24 周后接受 PORT 的患者。根据受试者工作特征分析,将 TTR 分为 8 周内和 8 周后。采用多变量 Cox 回归分析预测与生存显著相关的变量。
共有 1629 例患者符合分析条件。在 1629 例患者中,703 例患者在术后 8 周内接受了 PORT,926 例患者在术后 8 周后接受了 PORT。8 周后接受 PORT 与更好的 OS 相关(P =.0044)。早期和晚期 TTR 对同期组的生存无显著差异(P =.9119)。然而,对于增加 TTR 的序贯化疗,发现 OS 获益显著(P =.0045)。多变量分析显示,年龄较大、男性、旅行距离较短、淋巴结阳性率增加、肿瘤较大、Charlson/Deyo 合并症评分较高以及早期 TTR 与较差的生存相关。
在 PORT 中序贯化疗时,TTR ≥ 8 周与 pN2 期 NSCLC 患者的生存改善相关。